IN THE CLAIMS

Delete claims 155, 161, 167, 173-176, 183-186, 192-195 and 201-204.

Please amend claim 177 as follows:

177 (Amended). The therapeutic composition of claim 210 or 211, wherein said genetically-engineered monoclonal antibody is a single-chain antibody.

Please insert new claims 210-213 as follows:

210 (New). A therapeutic composition, comprising:

a pharmaceutical formulation comprising

(1) a pharmaceutically acceptable carrier and

(2)(a) a genetically-engineered antibody that inhibits aggregation of beta-amyloid or maintains the solubility of soluble beta-amyloid, or

(b) a fragment of the genetically-engineered antibody of (a) that inhibits aggregation of beta-amyloid or maintains the solubility of soluble beta-amyloid,

wherein said genetically-engineered antibody is obtained from a monoclonal antibody that

(i) inhibits aggregation of beta-amyloid or maintains the solubility of soluble beta-amyloid and

(ii) is obtainable using residues 1-28 of beta-amyloid as an immunogen or recognizes an epitope within residues 1-28 of beta-amyloid.

211 (New). The therapeutic composition of claim 210, wherein said genetically-engineered antibody of (2)(a) inhibits aggregation of human beta-amyloid or maintains the

solubility of soluble human beta-amyloid, or said fragment of (2)(b) inhibits aggregation of human beta-amyloid or maintains the solubility of soluble human beta-amyloid, and said genetically-engineered antibody of (2)(a) is obtained from a monoclonal antibody that inhibits aggregation of human beta-amyloid or maintains the solubility of soluble human beta-amyloid and said monoclonal antibody is obtainable using residues 1-28 of human beta-amyloid as an immunogen or recognizes an epitope within residues 1-28 of human beta-amyloid.

212 (New). A therapeutic composition, comprising:

a pharmaceutical formulation comprising

(1) a pharmaceutically acceptable carrier and

(2)(a) a human monoclonal antibody that inhibits aggregation of beta-amyloid or maintains the solubility of soluble beta-amyloid, or

(b) a fragment of the human monoclonal antibody of (a) that inhibits aggregation of beta-amyloid or maintains the solubility of soluble beta-amyloid,

wherein said human monoclonal antibody is obtainable using residues 1-28 of beta-amyloid as an immunogen.

213 (New). The therapeutic composition of claim 212, wherein said human monoclonal antibody of (2)(a) inhibits aggregation of human beta-amyloid or maintains the solubility of soluble human beta-amyloid, or said fragment of (2)(b) inhibits aggregation of human beta-amyloid or maintains the solubility of soluble human beta-amyloid, and wherein said

human monoclonal antibody of (a) is obtainable using residues 1-28 of human beta-amyloid as an immunogen.